Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model

Drug Delivery and Translational Research

Volumn 2, Issue 2, 2012, Pages 77-86

  Tagami, Tatsuaki ^a   Lila, Amr S Abu ^a,b   Matsunaga, Mariko ^a   Moriyoshi, Naoto ^a   Nakamura, Hiroyuki ^a   Nakamura, Kazuya ^a   Suzuki, Takuya ^a   Doi, Yusuke ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Zagazig University   (Egypt)

Author keywords

Argonaute2 (Ago2); Metronomic chemotherapy; PEG coated siRNA lipoplex; S 1; Small interfering RNA (siRNA)

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LIPOPLEX; MACROGOL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; KIDNEY; LEWIS CARCINOMA; LIVER; LUNG; MALE; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SPLEEN; TUMOR; TUMOR MODEL;

EID: 84864774906     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0059-1     Document Type: Article

References (41)

1. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004; 15: 185-97.
2. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest. 2007; 117: 3623-32.
3. Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med. 2010; 12: e26.
4. Haupenthal J, Baehr C, Kiermayer S, Zeuzem S, Piiper A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol. 2006; 71: 702-10.
5. Kim WJ, Chang CW, Lee M, Kim SW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Control Release. 2007; 118: 357-63.
6. Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res. 2004; 10: 7721-6.
7. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006; 13: 1222-34.
8. Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010; 277: 4814-27.
9. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4: 423-36.
10. Laquente B, Vinals F, Germa JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol. 2007; 9: 93-8.
11. Sanchez-Munoz A, Mendiola C, Perez-Ruiz E, Rodriguez-Sanchez CA, Jurado JM, Alonso-Carrion L, et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology. 2010; 79: 98-104.
12. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 2010; 9: 685-93.
13. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Canc. 2010; 17: 445-53.
14. Tang TC, Man S, Lee CR, Xu P, Kerbel RS. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia. 2010; 12: 264-74.
15. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S, Fukushima M. Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett. 2008; 267: 26-36.
16. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357: 1810-20.
17. Shiraga E, Barichello JM, Ishida T, Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int J Pharm. 2008; 353: 65-73.
18. Ishida T, Shiraga E, Kiwada H. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J Control Release. 2009; 134: 194-200.
19. Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci. 2010; 101: 2470-5.
20. Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther. 2011; 19: 2040-7.
21. Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci. 2010; 101: 1163-9.
22. Tagami T, Hirose K, Barichello JM, Ishida T, Kiwada H. Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes. Pharm Res. 2008; 25: 2497-504.
23. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release. 2009; 137: 234-40.
24. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem. 1959; 234: 469-71.
25. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999; 460: 129-33.
26. Harashima H, Yamane C, Kume Y, Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J Pharmacokinet Biopharm. 1993; 21: 299-308.
27. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release. 2009; 137: 8-14.
28. Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, Ishida T, et al. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm. 2011; 422(1-2): 280-9.
29. Tan FL, Yin JQ. RNAi, a new therapeutic strategy against viral infection. Cell Res. 2004; 14: 460-6.
30. Orlacchio A, Bernardi G, Martino S. RNA interference as a tool for Alzheimer's disease therapy. Mini Rev Med Chem. 2007; 7: 1166-76.
31. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, et al. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv. 2010; 28: 27-34.
32. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006; 2006: 71659.
33. Kim SH, Jeong JH, Kim TI, Kim SW, Bull DA. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm. 2009; 6: 718-26.
34. Hauser PV, Pippin JW, Kaiser C, Krofft RD, Brinkkoetter PT, Hudkins KL, et al. Novel siRNA delivery system to target podocytes in vivo. PLoS One. 2010; 5: e9463.
35. Finak G, Laferriere J, Hallett M, Park M. The tumor microenvironment: a new tool to predict breast cancer outcome. Med Sci (Paris). 2009; 25: 439-41.
36. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
37. Davies Cde L, Lundstrom LM, Frengen J, Eikenes L, Bruland SO, Kaalhus O, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res. 2004; 64: 547-53.
38. Deckers R, Moonen CT. Ultrasound triggered, image guided, local drug delivery. J Control Release. 2010; 148: 25-33.
39. Koning GA, Eggermont AM, Lindner LH, ten Hagen TL. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res. 2010; 27: 1750-4.
40. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A. 2007; 104: 3460-5.
41. Ten Hagen TL, van Der Veen AH, Nooijen PT, van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer. 2000; 87: 829-37.